No further trading action required, APLS shares are no longer publicly traded. Monitor CVR-related events for Biogen's acquisition consideration.
Price Chart
Executive Summary
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective May 26, 2026, following the completion of Biogen's acquisition. The company's common stock was delisted via a prior 25-NSE filing, and there is now only one holder of record, reflecting the acquisition's consummation. This is a procedural step after the merger, with no further impact on public shareholders.
Key Facts
- Form 15-12G filed to terminate registration under Section 12(g) of the Securities Exchange Act.
- Approximate number of holders of record as of certification date: one (1).
- Deregistration follows the completion of Biogen's acquisition (previous 25-NSE delisting on May 14, 2026).
- Common stock will cease SEC reporting obligations effective immediately.
Financial Impact
Shareholders received $41.00 per share plus contingent value rights (CVRs) from the Biogen acquisition; no new financial impact from this filing.
Risk Factors
- CVR value may fluctuate based on Apellis' clinical and regulatory outcomes under Biogen.
- Future litigation or liabilities may arise post-deregistration with limited public disclosure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0000950157-26-000636 |
| Document: 0000950157-26-000636-index-headers.html | 0000950157-26-000636 |
| Document: 0000950157-26-000636-index.html | 0000950157-26-000636 |
| Document: 0000950157-26-000636.txt | 0000950157-26-000636 |
Track record
5 reports on APLS
The track record builds as more bullish or bearish reports settle.
Filters
- May 26, 202624w ago 15-12G Neutral 6/10 Viewing No price data
- May 14, 202626w ago 25-NSE Neutral 2/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
- May 14, 202626w ago 8-K Bullish 8/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
- May 4, 202628w ago 8-K Neutral 2/10 Entry $40.97 to $40.97 · 0.00% −0.80% vs SPY
- Mar 27, 202633w ago Institutional Cluster Mixed 6/10 Entry $16.97 to $17.09 ▲ +0.71% +1.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers